AU2013322635C1 - Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications - Google Patents

Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications Download PDF

Info

Publication number
AU2013322635C1
AU2013322635C1 AU2013322635A AU2013322635A AU2013322635C1 AU 2013322635 C1 AU2013322635 C1 AU 2013322635C1 AU 2013322635 A AU2013322635 A AU 2013322635A AU 2013322635 A AU2013322635 A AU 2013322635A AU 2013322635 C1 AU2013322635 C1 AU 2013322635C1
Authority
AU
Australia
Prior art keywords
thr
pro
gly
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013322635A
Other languages
English (en)
Other versions
AU2013322635B2 (en
AU2013322635A1 (en
Inventor
Samantha Brandler
Philippe Despres
Andre Habel
Frederic Tangy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Themis Bioscience GmbH
Centre National de la Recherche Scientifique
Institut Pasteur
Original Assignee
Themis Bioscience GmbH
Centre National de la Recherche Scientifique
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Themis Bioscience GmbH, Centre National de la Recherche Scientifique, Institut Pasteur filed Critical Themis Bioscience GmbH
Publication of AU2013322635A1 publication Critical patent/AU2013322635A1/en
Publication of AU2013322635B2 publication Critical patent/AU2013322635B2/en
Application granted granted Critical
Publication of AU2013322635C1 publication Critical patent/AU2013322635C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18444—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013322635A 2012-09-27 2013-09-26 Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications Active AU2013322635C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306176.4 2012-09-27
EP12306176.4A EP2712871A1 (en) 2012-09-27 2012-09-27 Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
PCT/EP2013/070137 WO2014049094A1 (en) 2012-09-27 2013-09-26 Recombinant measles virus expressing chikungunya virus polypeptides and their applications

Publications (3)

Publication Number Publication Date
AU2013322635A1 AU2013322635A1 (en) 2015-04-02
AU2013322635B2 AU2013322635B2 (en) 2017-10-12
AU2013322635C1 true AU2013322635C1 (en) 2018-02-08

Family

ID=46982495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013322635A Active AU2013322635C1 (en) 2012-09-27 2013-09-26 Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications

Country Status (16)

Country Link
US (1) US9655961B2 (cg-RX-API-DMAC10.html)
EP (2) EP2712871A1 (cg-RX-API-DMAC10.html)
JP (1) JP6251273B2 (cg-RX-API-DMAC10.html)
KR (1) KR102077131B1 (cg-RX-API-DMAC10.html)
CN (1) CN104918952B (cg-RX-API-DMAC10.html)
AU (1) AU2013322635C1 (cg-RX-API-DMAC10.html)
BR (1) BR112015006763B1 (cg-RX-API-DMAC10.html)
CA (1) CA2884585C (cg-RX-API-DMAC10.html)
DK (1) DK2900687T3 (cg-RX-API-DMAC10.html)
ES (1) ES2682268T3 (cg-RX-API-DMAC10.html)
IN (1) IN2015DN02546A (cg-RX-API-DMAC10.html)
MX (1) MX359981B (cg-RX-API-DMAC10.html)
PH (1) PH12015500499A1 (cg-RX-API-DMAC10.html)
PT (1) PT2900687T (cg-RX-API-DMAC10.html)
SG (1) SG11201502411PA (cg-RX-API-DMAC10.html)
WO (1) WO2014049094A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI111811B (fi) * 1998-06-05 2003-09-30 Outokumpu Oy Menetelmä kuivauksen tehostamiseksi
WO2016122414A1 (en) * 2015-01-29 2016-08-04 Agency For Science, Technology And Research Nanocapsules carrying chikungunya-associated peptides
WO2017060360A1 (en) * 2015-10-06 2017-04-13 Invectys Polyepitope constructs for use in immunotherapy
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
WO2017221076A1 (en) 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
CA3030451C (en) * 2016-07-15 2023-09-05 Etubics Corporation Compositions and methods for alphavirus vaccination
KR101919403B1 (ko) * 2016-11-04 2018-11-16 연세대학교 원주산학협력단 재조합 단백질 및 그의 용도
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
CN118662621A (zh) * 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法
MX2020004833A (es) 2017-11-09 2021-01-08 Pasteur Institut Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
EP3581646A1 (en) 2018-06-15 2019-12-18 Themis Bioscience GmbH Integrated manufacturing and chromatographic system for virus production
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
CN115433741A (zh) * 2022-06-23 2022-12-06 广西大学 盖他病毒为载体表达报告蛋白的重组病毒的构建方法
CN117904059A (zh) * 2022-10-17 2024-04-19 清华大学 一种基于麻疹病毒载体包装病毒样颗粒冠状病毒疫苗的方法
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2545597A1 (en) 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2274442B1 (en) * 2008-04-04 2016-06-29 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
WO2011082388A2 (en) 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
WO2012106356A2 (en) * 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
CN102321639B (zh) * 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
MX357202B (es) * 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WATARU AKAHATA ET AL, vol. 16, no. 3, doi:10.1038/NM.2105, ISSN 1546-170X, (20100301), pages 334 - 338, NATURE MEDICINE, NATURE PUBLISHING GROUP, GB, *

Also Published As

Publication number Publication date
EP2900687B1 (en) 2018-05-02
BR112015006763B1 (pt) 2023-10-24
US20150238592A1 (en) 2015-08-27
MX359981B (es) 2018-10-18
DK2900687T3 (en) 2018-08-06
AU2013322635B2 (en) 2017-10-12
EP2712871A1 (en) 2014-04-02
SG11201502411PA (en) 2015-04-29
MX2015003717A (es) 2015-10-22
ES2682268T3 (es) 2018-09-19
CN104918952B (zh) 2019-01-22
PT2900687T (pt) 2018-08-06
CA2884585C (en) 2021-12-14
HK1211951A1 (en) 2016-06-03
AU2013322635A1 (en) 2015-04-02
PH12015500499B1 (en) 2015-04-27
JP2015532090A (ja) 2015-11-09
US9655961B2 (en) 2017-05-23
IN2015DN02546A (cg-RX-API-DMAC10.html) 2015-09-11
JP6251273B2 (ja) 2017-12-20
WO2014049094A1 (en) 2014-04-03
KR20150058506A (ko) 2015-05-28
PH12015500499A1 (en) 2015-04-27
EP2900687A1 (en) 2015-08-05
KR102077131B1 (ko) 2020-04-09
CA2884585A1 (en) 2014-04-03
BR112015006763A2 (pt) 2019-09-03
CN104918952A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
KR102077131B1 (ko) 치쿤구니야 바이러스 폴리펩티드를 발현하는 재조합 홍역 바이러스 및 이의 사용
KR101227128B1 (ko) 홍역 바이러스의 허가된 백신 종의 감염성 ｃＤＮＡ 및면역학적 조성물로서의 용도
JP7585382B2 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
US6635257B1 (en) Particles of HCV envelope proteins: use for vaccination
KR101241423B1 (ko) 알엔에이 바이러스 항원의 에피토프를 발현하는 재조합홍역 바이러스-백신 제제의 제조에 사용하기 위한 용도
US6168943B1 (en) Methods for making modified recombinant vesiculoviruses
KR101469007B1 (ko) 비분절 음성 가닥 ｒｎａ 바이러스 생성하는 세포 및 방법
KR102823029B1 (ko) 알파바이러스 레플리콘 입자
KR102335519B1 (ko) 인체 감염 사스코로나 바이러스 예방 및 감염 증상 완화용 백신 조성물
WO1996034625A9 (en) Recombinant vesiculoviruses and their uses
JPH10506782A (ja) 組換え型シチメンチョウヘルペスウイルス、及びその使用
KR20110070911A (ko) 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
CA2444006A1 (en) Expression of core-glycosylated hcv envelope proteins in yeast
CN112048484A (zh) 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN112094822B (zh) 基于EV71毒株的感染性cDNA克隆及其应用
KR20150065945A (ko) 홍역-말라리아 조합 백신
KR101085310B1 (ko) 감염성 점액낭병 바이러스 돌연변이체 및 백신
CN114703207B (zh) 重组质粒的制备方法和重组病毒
CN112553255A (zh) 一种表达传染性法氏囊病毒vp2抗原的重组病毒及制备与应用
RU2795596C2 (ru) Частица репликона альфавируса
JP3428666B2 (ja) 組換えマレック病ウイルスおよびその製法
KR20200101327A (ko) 키메릭 황열 지카 바이러스 균주

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 NOV 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 NOV 2017

FGA Letters patent sealed or granted (standard patent)